NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company’s Head of Investor Relations and Corporate Communications.
Ms. Bavishi brings more than 10 years of experience to Rallybio and will be responsible for overseeing Rallybio’s investor relations (IR) and communications efforts, including shaping the company’s IR and communications strategies. She will report to Steven Tuch, the company’s Head of Corporate Development.
“Ami is a fantastic addition to the Rallybio team, and her IR and communications skills round out the company’s already deep talent pool,” said Steven Tuch. “We look forward to tapping into her industry expertise as we continue to communicate Rallybio’s mission to develop and deliver unimagined therapies to change lives for those impacted by rare diseases.”
Prior to joining Rallybio, Ms. Bavishi was Director of Investor Relations at Aerie Pharmaceuticals Inc., where she oversaw all investor relations activities. Prior to Aerie, she held positions of increasing responsibility at Burns McClellan, a life sciences investor relations and public relations firm, including Vice President of Investor Relations. At Burns McClellan, Ms. Bavishi oversaw day-to-day investor relations and communications activities for multiple biotechnology companies. Ms. Bavishi also has experience as a business development professional at U.K. Trade and Investment, the business development arm of the U.K. government, where she sourced and developed bilateral investment and trade in the U.S. and U.K. life science sectors.
“I’m excited to join Rallybio, especially as the company seeks to make important advances of its rare disease pipeline candidates,” said Ms. Bavishi. “It’s an immense honor to help shape the company’s communications around its bold science.”
Ms. Bavishi earned her bachelor’s degree in biological sciences from Duquesne University and a master’s degree in public health from The George Washington University.
About Rallybio
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.
